No HIV infections seen in San Francisco PrEP users referred via primary care
First Brazilian PrEP data reinforce evidence that PrEP is most used by those at greatest risk
Open-label PrEP in Botswana: very high adherence and no HIV infections seen
PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently
Gay youth PrEP study finds good retention and reasonable adherence
Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing
Vancouver Consensus Statement calls for early access to treatment and PrEP worldwide
